Hologic Inc.
Hologic Reports Preliminary Q1 Revenue of $1.013B, Exceeding Guidance
Summary
Hologic, Inc. announced preliminary revenue results for Q1 2024 on January 7, 2024, reporting $1,013.1 million, which exceeded the guidance range of $960 to $985 million. Organic revenue excluding COVID-19 grew by 5.2%, also surpassing guidance. The company is expected to report non-GAAP diluted EPS towards the high end of the $0.92 to $0.97 guidance range. Full financial results are scheduled for release on February 1, 2024.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement